Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald J P Pinto

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 19, 2006
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residuesJennifer X Qiao, Xuhong Cheng, Joanne M Smallheer, et al.
Journal of Medicinal Chemistry|October 5, 2007
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Stephanie Koch, et al.
Journal of Medicinal Chemistry|March 18, 2005
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitorMimi L Quan, Patrick Y S Lam, Qi Han, et al.
Journal of Medicinal Chemistry|January 14, 2017
Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide LinkerJames R Corte, Tianan Fang, Honey Osuna, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2006
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moietiesDonald J P Pinto, Robert A Galemmo, Mimi L Quan, et al.
Bioorganic & Medicinal Chemistry|April 14, 2016
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime groupJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|December 19, 2006
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residuesJennifer X Qiao, Xuhong Cheng, Joanne M Smallheer, et al.
Journal of Medicinal Chemistry|October 5, 2007
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Stephanie Koch, et al.
Journal of Medicinal Chemistry|March 18, 2005
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitorMimi L Quan, Patrick Y S Lam, Qi Han, et al.
Journal of Medicinal Chemistry|January 14, 2017
Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide LinkerJames R Corte, Tianan Fang, Honey Osuna, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2006
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moietiesDonald J P Pinto, Robert A Galemmo, Mimi L Quan, et al.
Bioorganic & Medicinal Chemistry|April 14, 2016
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime groupJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Pageof 3